Unknown

Dataset Information

0

Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.


ABSTRACT: BACKGROUND:Breast cancer is the most prevalent tumor entity in Li-Fraumeni syndrome. Up to 80% of individuals with a Li-Fraumeni-like phenotype do not harbor detectable causative germline TP53 variants. Yet, no systematic panel analyses for a wide range of cancer predisposition genes have been conducted on cohorts of women with breast cancer fulfilling Li-Fraumeni(-like) clinical diagnostic criteria. METHODS:To specifically help explain the diagnostic gap of TP53 wild-type Li-Fraumeni(-like) breast cancer cases, we performed array-based CGH (comparative genomic hybridization) and panel-based sequencing of 94 cancer predisposition genes on 83 breast cancer patients suggestive of Li-Fraumeni syndrome who had previously had negative test results for causative BRCA1, BRCA2, and TP53 germline variants. RESULTS:We identified 13 pathogenic or likely pathogenic germline variants in ten patients and in nine genes, including four copy number aberrations and nine single-nucleotide variants or small indels. Three patients presented as double-mutation carriers involving two different genes each. In five patients (5 of 83; 6% of cohort), we detected causative pathogenic variants in established hereditary breast cancer susceptibility genes (i.e., PALB2, CHEK2, ATM). Five further patients (5 of 83; 6% of cohort) were found to harbor pathogenic variants in genes lacking a firm association with breast cancer susceptibility to date (i.e., Fanconi pathway genes, RECQ family genes, CDKN2A/p14ARF, and RUNX1). CONCLUSIONS:Our study details the mutational spectrum in breast cancer patients suggestive of Li-Fraumeni syndrome and indicates the need for intensified research on monoallelic variants in Fanconi pathway and RECQ family genes. Notably, this study further reveals a large portion of still unexplained Li-Fraumeni(-like) cases, warranting comprehensive investigation of recently described candidate genes as well as noncoding regions of the TP53 gene in patients with Li-Fraumeni(-like) syndrome lacking TP53 variants in coding regions.

SUBMITTER: Penkert J 

PROVIDER: S-EPMC6081832 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.

Penkert Judith J   Schmidt Gunnar G   Hofmann Winfried W   Schubert Stephanie S   Schieck Maximilian M   Auber Bernd B   Ripperger Tim T   Hackmann Karl K   Sturm Marc M   Prokisch Holger H   Hille-Betz Ursula U   Mark Dorothea D   Illig Thomas T   Schlegelberger Brigitte B   Steinemann Doris D  

Breast cancer research : BCR 20180807 1


<h4>Background</h4>Breast cancer is the most prevalent tumor entity in Li-Fraumeni syndrome. Up to 80% of individuals with a Li-Fraumeni-like phenotype do not harbor detectable causative germline TP53 variants. Yet, no systematic panel analyses for a wide range of cancer predisposition genes have been conducted on cohorts of women with breast cancer fulfilling Li-Fraumeni(-like) clinical diagnostic criteria.<h4>Methods</h4>To specifically help explain the diagnostic gap of TP53 wild-type Li-Frau  ...[more]

Similar Datasets

| S-EPMC3135649 | biostudies-literature
| S-EPMC5629188 | biostudies-literature
| S-EPMC9381642 | biostudies-literature
| S-EPMC8785220 | biostudies-literature
| S-EPMC6371746 | biostudies-literature
| S-EPMC3831081 | biostudies-literature
| S-EPMC3646199 | biostudies-literature
| S-EPMC8531574 | biostudies-literature
| S-EPMC4123210 | biostudies-literature
| S-EPMC2806900 | biostudies-literature